Medication for Insomnia: What Works, What Doesn't, and What to Know Before You Start

CBT-I is the first-line treatment for chronic insomnia according to every major sleep society guideline. Multiple meta-analyses show it outperforms sleep medication in long-term outcomes — specifically because it addresses the behavioral and cognitive patterns that perpetuate chronic insomnia, not just the symptom of sleeplessness.

The core components of CBT-I:

• Stimulus control: re-associating the bed with sleep and sex only — not with wakefulness, phone scrolling, or anxious lying awake. The goal is to rebuild the conditioned association between bed and sleepiness that insomnia erodes. Key rules: get out of bed after 20 minutes of lying awake, don't lie in bed reading or watching TV, don't go to bed until you are sleepy.
• Sleep restriction: the counterintuitive cornerstone of CBT-I. Sleep restriction temporarily reduces time in bed to match actual sleep time (typically 5–6 hours initially), building sleep pressure and driving sleep efficiency toward 85–90%. Once efficiency improves, time in bed is extended. This is distinctly uncomfortable in the short term but is the most evidence-based component of CBT-I.
• Cognitive restructuring: addressing the catastrophic thoughts about sleep that perpetuate hyperarousal at bedtime — “I need 8 hours to function,” “If I don't fall asleep in the next 10 minutes my day tomorrow is ruined,” “My insomnia is destroying my health.” These thoughts are physiologically activating and directly undermine sleep onset.

CBT-I is available via licensed therapists, structured digital programs (Sleepio, CBTI Coach), and increasingly through telehealth. Medication is a reasonable adjunct or alternative when CBT-I is unavailable, not effective enough, or for acute insomnia where short-term relief is the goal.

Acute insomnia is defined as less than 3 months in duration — typically triggered by a stressor (job loss, grief, illness, major life transition). It often resolves on its own when the stressor resolves. Short-term sleep medication is often appropriate here: the goal is preventing acute sleep deprivation from becoming entrenched.

Chronic insomnia is difficulty falling asleep, staying asleep, or non-restorative sleep at least 3 nights per week for at least 3 months, with significant daytime impairment. By the time insomnia is chronic, behavioral and cognitive perpetuating factors have typically taken over from the original trigger. The original stressor may be long gone, but the insomnia persists because of conditioned arousal, sleep effort, and clock-watching. This is why CBT-I is essential for chronic insomnia — medication alone does not address these maintaining factors.

A normal night of sleep consists of alternating NREM and REM cycles, each roughly 90 minutes long:

• N1 (NREM stage 1): light sleep, transition from wakefulness — easily disrupted, not restorative
• N2 (NREM stage 2): deeper sleep with sleep spindles and K-complexes; sleep consolidation and memory processing occur here
• N3 (NREM stage 3, slow-wave sleep): deep, physically restorative sleep — growth hormone is released here, immune consolidation happens, and the physical recovery from the day occurs. This is the sleep that makes you feel rested.
• REM: dreaming sleep — emotionally consolidating, essential for memory integration, mood regulation, and cognitive processing. Disrupted REM is associated with increased emotional reactivity and reduced emotional resilience the following day.

This matters pharmacologically because different sleep medications affect sleep architecture differently. Benzodiazepines suppress N3 and alter REM — they produce sleep, but often not the most restorative kind. Some newer options (orexin antagonists) are specifically designed to preserve or enhance N3 and REM.

OTC Options: Antihistamines and Melatonin

Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs) and doxylamine (Unisom SleepMelts): First-generation antihistamines that cross the blood-brain barrier and cause sedation as a side effect. Quick tolerance develops within days of regular use, so they are not effective for chronic insomnia. They also produce a significant “hangover” — morning grogginess, cognitive impairment, dry mouth, urinary retention. In older adults, the anticholinergic burden is a meaningful concern — associated with falls, cognitive impairment, and worsened urinary symptoms.

Melatonin: The endogenous hormone that signals darkness to the circadian clock. The standard OTC dose (5–10mg) is physiologically excessive — the body produces approximately 0.1–0.3mg of melatonin in the evening. Research consistently shows that 0.5–1mg timed 60–90 minutes before the target sleep time is more effective for sleep onset than 5–10mg taken at bedtime. The high doses most people take cause a surge-and-crash pattern that can actually worsen sleep quality. Melatonin is most useful for sleep onset (not maintenance), for circadian rhythm disruption (jet lag, shift work), and as a low-risk first step for mild insomnia.

Z-Drugs: Zolpidem, Eszopiclone, Zaleplon

Z-drugs are GABA-A receptor positive modulators with selectivity for the BZ1 subunit (associated with sedation) vs. BZ2 (associated with muscle relaxation and anxiolysis). This selectivity was supposed to make them safer than benzodiazepines — and in some respects it does (shorter half-life, less daytime impairment at standard doses). However, tolerance and dependence still develop with regular use, and rebound insomnia on discontinuation is significant.

More importantly: Z-drugs carry a distinctive risk profile that includes complex sleep behaviors — sleepwalking, sleep-eating, sleep-driving — with no memory of the events. These are rare but well-documented. In 2019, the FDA added a black box warning and required new warnings.

A notable regulatory data point: in 2013, the FDA halved the recommended zolpidem dose for women (from 10mg to 5mg) after data showed women metabolize zolpidem more slowly, leaving blood levels high enough at 7–8 hours to impair driving — even in women who felt fully awake.

Benzodiazepines: Temazepam, Triazolam

Benzodiazepines are effective sleep medications in the short term. They increase total sleep time, reduce awakenings, and reduce sleep latency. The clinical problem is the risk profile for chronic use: tolerance develops within days to weeks, dependence follows, and discontinuation produces rebound insomnia that can substantially exceed the original insomnia — driving continued use.

Benzos also suppress N3 (slow-wave) sleep and alter REM architecture — the sleep they produce is shallower and less physically restorative than natural sleep. For acute short-term use (1–2 weeks), they are a reasonable option. For chronic insomnia, they are not recommended.

Orexin Antagonists: Suvorexant and Lemborexant

The newest class of sleep medications and a mechanistically distinct approach: instead of sedating the brain, orexin antagonists block the wakefulness-promoting signal. Orexin (also called hypocretin) is the neurotransmitter that keeps you awake — suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin receptors, reducing the brain's drive to stay awake rather than forcing sedation.

Clinical advantages: no significant rebound insomnia, better preservation of REM sleep, and no known physical dependence liability. They are particularly appropriate for patients who are concerned about dependence, who have had problems with Z-drug or benzo dependence, or who want to avoid sedating medications. Suvorexant is dosed at 10–20mg. Side effects are generally mild — next-day somnolence at higher doses; rarely, sleep paralysis or hypnagogic hallucinations.

Low-Dose Doxepin (Silenor)

Doxepin is a tricyclic antidepressant with potent H1 (histamine) antagonism. At its antidepressant dosing range (75–300mg), it produces significant anticholinergic side effects. At very low doses (3–6mg), it is essentially a pure H1 antagonist — selectively prolonging sleep at the end of the night (sleep maintenance insomnia) with minimal anticholinergic burden at those doses. The FDA approved doxepin 3mg and 6mg specifically for insomnia characterized by difficulty maintaining sleep. It is non-scheduled, has no dependence liability, and is often well-tolerated in older adults at these micro-doses.

Trazodone (Off-Label)

Trazodone is widely used for insomnia in clinical practice — arguably the most commonly prescribed off-label sleep medication in psychiatry. It is an antidepressant at higher doses (150–600mg) but is used at 50–150mg for sleep. The mechanism is primarily H1 and alpha-1 antagonism at these lower doses, with some serotonin receptor activity. The evidence base for insomnia is thinner than its use would suggest — there are relatively few high-quality RCTs specifically for insomnia. However, it is non-scheduled, non-habit-forming, and particularly useful when depression or anxiety co-occur with insomnia. Rare but notable side effect: priapism (prolonged, painful erection) — patients should be counseled to seek urgent care if an erection persists more than 4 hours.

Ramelteon (Rozerem)

A melatonin receptor agonist (MT1/MT2) — the only FDA-approved sleep medication that is not a controlled substance. Ramelteon targets circadian rhythm regulation rather than producing sedation, so it is effective for sleep onset but not sleep maintenance. It has no dependence liability, no rebound insomnia, and no significant next-day impairment. Effects are modest compared to other prescription options. Most useful in older adults, patients who need to avoid controlled substances, and patients whose insomnia is primarily circadian (trouble falling asleep, not trouble staying asleep).

Gabapentin and Pregabalin (Off-Label)

Both reduce neuronal excitability via voltage-gated calcium channel modulation. Used off-label for insomnia — most often in patients who also have comorbid pain (fibromyalgia, neuropathic pain), anxiety, or alcohol use disorder (where gabapentin has separate evidence). They increase N3 sleep and reduce nighttime awakenings. Misuse potential exists, particularly for pregabalin (Schedule V) and gabapentin in populations with substance use history — prescribers should weigh this carefully.

Low-Dose Quetiapine (Off-Label)

Quetiapine at low doses (12.5–50mg) is heavily sedating due to H1 antagonism — and is widely prescribed off-label for insomnia despite minimal evidence for this use. The metabolic risk profile (weight gain, glucose dysregulation, dyslipidemia) makes it a poor choice for insomnia without a comorbid psychiatric indication. Prescribing low-dose quetiapine for insomnia in patients without bipolar disorder or schizophrenia exposes them to an antipsychotic's metabolic risks for a condition with better alternatives.

Standard sleep hygiene advice (“avoid screens, have a consistent bedtime”) is not wrong, but it misses several clinically important factors:

Chronotype Mismatch

Chronotype — whether you are a morning lark or evening owl — is substantially genetically determined. About 25% of the population are true evening chronotypes who have a naturally delayed circadian phase. When evening chronotypes are required to wake at 6am for work, they are chronobiologically incapable of feeling sleepy at 10pm, no matter what they do. The result is a structurally chronic sleep deficit that gets labeled as insomnia — but is really a circadian mismatch. Light therapy in the morning and low-dose melatonin in the early evening (not at bedtime) can help shift the circadian phase forward.

Social Jet Lag

Social jet lag refers to the discrepancy between a person's biological clock and their socially required sleep schedule — typically sleeping late on weekends and waking early on weekdays. This weekly two-night shift resets the circadian clock backward, making Monday morning biologically equivalent to crossing several time zones. For chronic insomnia patients, the weekend sleep schedule is often doing as much damage as anything else in their routine.

Blue Light and the Retinal Pathway

Blue wavelength light (from screens, LED lighting, device backlight) is detected by intrinsically photosensitive retinal ganglion cells (ipRGCs) that project directly to the suprachiasmatic nucleus — the circadian pacemaker. Blue light in the 1–2 hours before sleep suppresses melatonin secretion and sends a “daylight” signal to the circadian clock. Amber-tinted glasses or screen filters that reduce blue light emission work — not by reducing screen brightness, but by eliminating the specific wavelength the ipRGC pathway responds to.

Rebound insomnia occurs when stopping a sleep medication produces worse insomnia than the original — due to the brain's compensatory upregulation of arousal circuits during chronic sedative use. It is most significant with benzodiazepines and Z-drugs (especially zolpidem) and is a primary driver of continued use despite the intention to stop.

Safe tapering principles:

• Taper slowly — reduce by no more than 10–25% of the current dose every 1–2 weeks
• Switch from a short-acting to a longer-acting benzodiazepine (e.g., diazepam) before tapering, if possible — the longer half-life smooths the withdrawal curve
• Implement CBT-I simultaneously — the behavioral skills provide an alternative structure to support sleep during taper
• Expect some sleep disruption during taper, particularly in the first week after each reduction — prepare for it rather than interpreting it as treatment failure
• Do not stop abruptly if dependence has developed — benzodiazepine withdrawal can produce seizures in severe dependence and should be medically supervised